GlaxoSmithKline (GSK) has announced its experimental drug belantamab mafodotin (GSK2857916) has met its...
- GSK’s belantamab mafodotin performs well in refractory multiple myeloma
- Medidata CEO Tarek Sherif on the past and future of pharma R&D
- AstraZeneca’s Imfinzi fails to meet endpoint in Stage IV NSCLC
- AstraZeneca’s diabetes drug Farxiga performs well in heart failure patients
- FDA approves first non-controlled substance narcolepsy drug
GSK’s belantamab mafodotin performs well in refractory multiple myeloma
GlaxoSmithKline (GSK) has announced its experimental drug belantamab mafodotin (GSK2857916) has met its primary endpoint in the DREAMM-2 trial of patients with relapsed and refractory multiple myeloma.
Avoiding pricy clinical research delays
A vast majority of clinical trials face postponements, costing precious time and money and impacting patients, which why managing time, resources and participants are crucial in avoiding delays and providing results.
Medidata CEO Tarek Sherif on the past and future of pharma R&D
This year marks Medidata’s 20th anniversary; it is the also the year it will be acquired by Dassault. The company’s CEO and co-founder Tarek Sherif reflects on how the clinical development space has evolved in the past two decades and predicts the main drivers of the industry’s future transformation.
AstraZeneca’s Imfinzi fails to meet endpoint in Stage IV NSCLC
AstraZeneca has announced that Imfinzi (durvalumab), combined with tremelimumab, failed to achieve its primary endpoint in the Phase III NEPTUNE trial of patients with previously-untreated Stage IV non-small cell lung cancer (NSCLC).
AstraZeneca’s diabetes drug Farxiga performs well in heart failure patients
AstraZeneca has announced that Farxiga (dapagliflozin) met its primary endpoint in heart failure-focused Phase III DAPA-HF trial of patients with reduced ejection fraction (HFrEF).
FDA approves first non-controlled substance narcolepsy drug
Harmony Biosciences has announced the US Food and Drug Administration (FDA) has approved Wakix (pitolisant) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy.
AstraZeneca and Merck’s Lynparza continues to perform well in ovarian cancer
AstraZeneca and Merck have announced that Lynparza (olaparib), the primary product in their ongoing oncology collaboration, has performed better than the standard of care as a first line maintenance treatment for patients with ovarian cancer, regardless of BRCA status.
Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasis
Eli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.